Physician profile
Edison L Ong
NPI 1598794406
$2,556.30
in general payments reported to CMS, 2019-2025
28 companies · $595 in 2025
The $595 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $88.64 · 2021: $346 · 2022: $281 · 2023: $742 · 2024: $311 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $578.02 | 2020-2025 | Aristada, Lybalvi |
| Abbvie INC. | $279.96 | 2021-2025 | |
| Ironshore Pharmaceuticals INC. | $165.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $150.00 | 2025 | |
| Amgen INC. | $132.01 | 2023-2025 | Krystexxa, Repatha, Otezla |
| Indivior INC. | $129.87 | 2023 | Perseris |
| Corium, LLC | $111.47 | 2023-2024 | Azstarys |
| Axsome Therapeutics, INC. | $110.36 | 2025 | Auvelity |
| Pfizer INC. | $100.76 | 2021-2024 | |
| Lilly USA, LLC | $86.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sunovion Pharmaceuticals INC. | $82.72 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $75.63 | 2024 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $68.59 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $64.20 | 2024-2025 | Breztri, Airsupra |
| Grt US Holding, INC. | $61.99 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $57.41 | 2022-2025 | |
| Gilead Sciences, INC. | $41.62 | 2023-2024 | |
| Exact Sciences Corporation | $38.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.00 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $28.38 | 2023 | Spravato |
| Dexcom, INC. | $26.80 | 2023 | Dexcom G6 Transmitter |
| Vbi Vaccine (Delaware) INC. | $26.66 | 2023 | Prehevbrio |
| Vanda Pharmaceuticals INC. | $25.43 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $22.80 | 2023 | Ingrezza |
| Eisai INC. | $16.50 | 2021 | |
| Abbott Laboratories | $16.33 | 2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.85 | 2025 | Jardiance |
| Allergan, INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edison Ong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.